vardenafil-dihydrochloride has been researched along with Infertility--Male* in 2 studies
1 review(s) available for vardenafil-dihydrochloride and Infertility--Male
| Article | Year |
|---|---|
PDE5 inhibitors and male reproduction: Is there a place for PDE5 inhibitors in infertility clinics or andrology laboratories?
The objective of this review study is to evaluate the therapeutic role of PDE5 inhibitors (PDE5is) in the amelioration of oligoasthenospermia in infertile males. PDE5is have a beneficial influence on the secretory function of the Leydig and Sertoli cells, the biochemical environment within the seminiferous tubule, the contractility of the testicular tunica albuginea, and the prostatic secretory function. In several studies, the overall effect of sildenafil and vardenafil increased quantitative and qualitative sperm motility. Furthermore, some studies indicate that PDE5is influence positively the sperm capacity to undergo capacitation under biochemical conditions that are known to induce the sperm capacitation process. Additional research efforts are necessary in order to recommend unequivocally the usage of sildenafil, vardenafil, or avanafil for the alleviation of male infertility. Topics: Andrology; Fertility Clinics; Humans; Infertility, Male; Laboratories; Male; Phosphodiesterase 5 Inhibitors; Piperazines; Purines; Reproduction; Semen; Sildenafil Citrate; Sperm Motility; Sulfones; Vardenafil Dihydrochloride | 2022 |
1 trial(s) available for vardenafil-dihydrochloride and Infertility--Male
| Article | Year |
|---|---|
Effect of vardenafil on semen parameters in infertile men: a pilot study evaluating short-term treatment.
Severeal in vivo and in vitro studies have been carried out in order to evaluate the efficacy of long-term treatment with phosphodiesterase type-5 (PDE5) inhibitors (PDE5i) on spermatogenesis, but the results are still controversial.. To evaluate the effects of vardenafil on seminal parameters of infertile men after a short-term treatment.. A total of 205 male subjects were randomized to receive a single dose of vardenafil 10 mg (73 men, group B), a single dose of vardenafil 10 mg every other day for 15 days (67 men, group C), and no treatment (65 men, group A). Semen parameters were evaluated before and after the end of the treatment in each of group A, B, and C, respectively. Additionally, an IIEF- 5 questionnaire was administered to all patients with erectile dysfunction (ED) before and after each treatment period.. The semen parameters in groups B and C has shown a significant increase in percentage forward motility after vardenafil administration as compared with baseline (p<0.001). In group C, we observed an increase in the mean semen volume and an improvement in the mean total sperm concentration (p<0.001) as compared with baseline.. We showed the efficacy of vardenafil in the treatment of ED and, on a large series of infertile patients, the positive effect on sperm motility after a single-dose administration. It also showed that after 15 days of treatment on alternate days is also achieved an improvement in sperm concentration. Topics: Adult; Humans; Imidazoles; Infertility, Male; Male; Phosphodiesterase Inhibitors; Pilot Projects; Piperazines; Prognosis; Semen; Sperm Motility; Sulfones; Surveys and Questionnaires; Triazines; Vardenafil Dihydrochloride | 2012 |